Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Par Drugs & Che.
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 24.49 | 22.93 | 25.89 | 24.00 | 22.82 | 22.61 | 34.66 | 21.38 | 22.33 | 26.05 | 28.66 | 29.34 | 19.61 |
| Expenses + | 19.10 | 18.79 | 18.53 | 18.77 | 16.72 | 18.37 | 23.25 | 19.95 | 19.90 | 22.49 | 22.60 | 23.29 | 18.17 |
| Operating Profit | 5.39 | 4.14 | 7.36 | 5.23 | 6.10 | 4.24 | 11.41 | 1.43 | 2.43 | 3.56 | 6.06 | 6.05 | 1.44 |
| OPM % | 22.01% | 18.05% | 28.43% | 21.79% | 26.73% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% | 21.14% | 20.62% | 7.34% |
| Other Income + | 0.03 | 0.01 | 0.05 | 0.23 | -0.05 | 0.07 | 1.02 | 0.27 | 0.79 | 1.84 | 0.48 | 1.33 | 0.36 |
| Interest | 0.03 | 0.02 | 0.03 | 0.02 | 0.05 | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | 0.05 | 0.01 | 0.04 |
| Depreciation | 0.85 | 0.83 | 0.85 | 0.87 | 0.89 | 0.90 | 0.91 | 0.91 | 0.92 | 0.90 | 0.94 | 0.93 | 0.93 |
| Profit before tax | 4.54 | 3.30 | 6.53 | 4.57 | 5.11 | 3.39 | 11.49 | 0.78 | 2.28 | 4.48 | 5.55 | 6.44 | 0.83 |
| Tax % | 24.01% | 25.15% | 25.27% | 25.16% | 27.20% | 25.07% | 25.15% | 24.36% | 27.63% | 25.67% | 25.59% | 25.47% | -3.61% |
| Net Profit + | 3.45 | 2.47 | 4.89 | 3.42 | 3.72 | 2.53 | 8.60 | 0.58 | 1.65 | 3.33 | 4.13 | 4.80 | 0.85 |
| EPS in Rs | 2.80 | 2.01 | 3.97 | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.71 | 3.36 | 3.90 | 0.69 |
Financials of Par Drugs & Che.
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 96 | 101 | 104 |
| Expenses + | 26 | 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 73 | 81 | 87 |
| Operating Profit | 7 | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 23 | 20 | 17 |
| OPM % | 22% | 22% | 17% | 19% | 18% | 17% | 26% | 22% | 19% | 24% | 19% | 17% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 4 |
| Interest | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 1 | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 20 | 18 | 17 |
| Tax % | 27% | 58% | 42% | 42% | 24% | 21% | 21% | 27% | 25% | 26% | 26% | 24% |
| Net Profit + | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 14 | 13 | 13 |
| EPS in Rs | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 10.86 | 10.65 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Par Drugs & Che.
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 4 | 6 | 6 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 9 | 9 | 11 | 12 | 25 | 34 | 46 | 48 | 59 | 73 | 87 | 100 |
| Borrowings + | 38 | 36 | 31 | 29 | 12 | 6 | 8 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities + | 9 | 10 | 12 | 10 | 11 | 13 | 16 | 19 | 18 | 16 | 20 | 17 |
| Total Liabilities | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 102 | 119 | 129 |
| Fixed Assets + | 45 | 43 | 42 | 39 | 36 | 34 | 30 | 34 | 38 | 41 | 39 | 36 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 27 |
| Other Assets + | 13 | 15 | 14 | 15 | 15 | 25 | 42 | 44 | 50 | 60 | 55 | 65 |
| Total Assets | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 102 | 119 | 129 |
Financials of Par Drugs & Che.
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 9 | 7 | 9 | 4 | 2 | 8 | 12 | 8 | 13 | 20 | 16 | 16 |
| Cash from Investing Activity + | -0 | -0 | -2 | -1 | -0 | -1 | 0 | -3 | -7 | -6 | -25 | -2 |
| Cash from Financing Activity + | -9 | -5 | -8 | -4 | -2 | 1 | 2 | -10 | 0 | 0 | 0 | 0 |
| Net Cash Flow | -1 | 1 | -1 | 0 | -0 | 7 | 14 | -5 | 6 | 14 | -9 | 14 |
| Free Cash Flow | 9 | 6 | 7 | 4 | 2 | 6 | 12 | 4 | 6 | 14 | 15 | 14 |
| CFO/OP | 127% | 91% | 116% | 59% | 34% | 90% | 98% | 66% | 97% | 108% | 106% | 125% |
Financials of Par Drugs & Che.
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 81 | 61 | 75 | 67 | 81 | 75 | 90 | 65 | 52 | 60 | 42 |
| Inventory Days | 111 | 158 | 69 | 83 | 81 | 45 | 50 | 60 | 49 | 45 | 58 | 45 |
| Days Payable | 184 | 183 | 135 | 107 | 94 | 96 | 112 | 135 | 73 | 58 | 104 | 69 |
| Cash Conversion Cycle | 10 | 57 | -5 | 51 | 55 | 30 | 13 | 14 | 40 | 40 | 15 | 19 |
| Working Capital Days | 61 | 66 | -46 | -26 | 13 | 39 | 24 | 61 | 50 | 40 | 39 | 31 |
| ROCE % | 10% | 9% | 12% | 11% | 12% | 16% | 25% | 22% | 23% | 25% | 18% | 17% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…